Investor Presentation - First Six Months of 2021

108 Investor presentation First six months of 2021 Innovation drives largest transition in the history of Novo Nordisk USA, turning around 70% of sales in just seven years GLP-1 Directional growth drivers and catalysts Obesity • OzempicⓇ launch RybelsusⓇ launch Victoza® LoE • WegovyTM launch • SaxendaⓇ LOE 100% Insulin Biopharm 80% Continued price pressure Competitive 60% pressure • Biosimilar competition New product launches 40% 20% 1 Modern insulin, human insulin, PrandinⓇ, devices and needles; 2 Ozempic® and Rybelsus®: 3 Tresiba®, Xultophy®, Fiasp® and follow-on brand insulin LoE: Loss of exclusivity 0% NAO Relative sales composition - 57% transformation complete 2015 Biopharm Mature insulin¹ 2022 Victoza® Obesity New GLP-1 launches² New insulin launches³ 30%

View entire presentation